Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Regulatory Approval Obesity Treatments Lenacapavir Nanobody Technology FDA Approval Zaltenibart Semaglutide Monoclonal Antibodies Weight-loss Drugs Weight Loss Drugs Side Effects CT-996 Safety Testing Investigational Drugs GLP-1 Medications Lecanemab Wegovy Lung Cancer Liraglutide Tirzepatide PURPOSE 2 Study Bristol Myers Squibb Cobenfy Anti-Obesity Drugs Eli Lilly and Company Disease-Modifying Therapies Patient Safety Alzheimer's Disease Regulatory Approvals Emrosi Intra-Cellular Therapies Preventive Medicine GSK Prostate Cancer Treatments Idiopathic Pulmonary Fibrosis Eli Lilly Dry Eye Disease Benefits Obesity Treatment Liver Disease Treatment Competition in Obesity Market Phase I Trial Phase II Trial Neurological Conditions Drug Withdrawal Bayer Nonhormonal Treatments Esketamine Malaria Treatment PBS Listing Itepekimab Mounjaro Acquisition Elinzanetant Acute Myeloid Leukaemia Bladder Cancer Treatments FDA Regulations Safety Profiles Teplizumab Multiple Myeloma Gene Therapy Atopic Dermatitis Relutrigine FDA Approvals Small Molecules Alzheimer's Drugs GLP-1 Inhibitors WAYPOINT Phase III Trial Cardiovascular Disease Atopic Dermatitis Treatments Immunology Treatments Regulatory Issues Regulatory Affairs Efficacy and Safety Phase 3 Trials Orforglipron Endocrine Diseases Endocrine Therapies Patient Care AI in Clinical Trials Brensocatib Personalized Medicine GLP-1 Therapies VESALIUS-CV Anti-Malarial Drugs Malaria Treatments Efzofitimod Ulcerative Colitis Ovarian Cancer Treatments New Drug Applications Felzartamab Eli Lilly and Co Market Clearance Phase 3 Trial Obstructive Sleep Apnea Late-Stage Clinical Trial Dose Optimization Efficacy Obesity Weight Loss

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

FDA could issue a U.S. decision by March 28 under a faster review timeline, according to Reuters.

JPMorgan Upgrades Recursion, Raises Target to $11 as Shares Surge on AI Drug Signals

Novo Nordisk Presses India Expansion and Higher-Dose Push as Analyst Views Diverge

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

MoonLake Investors Courted by Law Firms as Lead‑Plaintiff Deadline Nears in SDNY Securities Case

aTyr Securities Suits Intensify as New Filing Expands Class Period Ahead of Dec. 8 Deadline

First New Antimalarial in Decades Tops 97% Cure in Phase III as Novartis Seeks Approval

MoonLake Investors Face Dec. 15 Deadline in Securities Suits Over Sonelokimab Claims

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

Regeneron Tops Q3 Forecasts on Dupixent Strength as Eylea HD Faces FDA Delay

FDA Approves Lynkuet, a Nonhormonal Pill for Menopausal Hot Flashes

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

AI Pinpoints Target of New IBD Antibiotic Enterololin, Speeding Development

Crinetics Wins FDA Approval for Oral Acromegaly Drug Palsonify as JMP Lifts Price Target

EU Panel Backs Tezspire for Chronic Rhinosinusitis With Nasal Polyps

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

FDA Grants Accelerated Approval to Forzinity, First Therapy for Barth Syndrome

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Semaglutide Curbs Cocaine Use and Relapse-Seeking in Rats, Peer-Reviewed Study Finds